Medscape3d
Despite Price Caps, Some Still Struggle to Access Insulin
While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
pharmaphorum5d
Civica plans shake-up of insulin sector with low-cost biosimilars
The average wholesale prices of the originator insulin are around $329 per vial and $510 for five pens, according to Civica, which says it will start clinical trials of the biosimilars this year ...
Minnesota Daily11d
Insulin costs capped at $35 per month in Minnesota
Minnesota Attorney General Keith Ellison and pharmaceutical company Novo Nordisk reached a settlement to cap insulin costs at ...
pharmaphorum5d
California sues insulin producers and PBMs over pricing
"High list prices also make insulin unaffordable for other patients ... will cost no more than $30 per vial or $55 for five pen cartridges, adding that compares to around $329 per vial and $ ...
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
BioSpace5d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...
Monthly Prescribing Reference4d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.